Pharmaco-epidemiology in 136 hospitalized schizophrenic patients
The authors surveyed pharmacotherapy in a group of 136 newly admitted patients with a DSM-III diagnosis of schizophrenia. They found that nine antipsychotic agents were used; the median daily dose (in chlorpromazine equivalents) was 1088 mg (mean +/- SD = 1428 +/- 1260 mg; range = 75-6186 mg). Women...
Gespeichert in:
| Veröffentlicht in: | The American journal of psychiatry 1987-06, Vol.144 (6), p.778-782 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 782 |
|---|---|
| container_issue | 6 |
| container_start_page | 778 |
| container_title | The American journal of psychiatry |
| container_volume | 144 |
| creator | ZITO, J. M CRAIG, T. J WANDERLING, J SIEGEL, C |
| description | The authors surveyed pharmacotherapy in a group of 136 newly admitted
patients with a DSM-III diagnosis of schizophrenia. They found that nine
antipsychotic agents were used; the median daily dose (in chlorpromazine
equivalents) was 1088 mg (mean +/- SD = 1428 +/- 1260 mg; range = 75-6186
mg). Women received greater mean daily doses of antipsychotics than men
(1688 versus 1284 mg). Using a Cox model survival analysis, the authors
found no statistical association between length of stay and the mean daily
dose of antipsychotic medication. The mean daily dose of high-potency
agents was 2.7 times greater than the dose of low-potency agents. The
excess exposure to haloperidol alone resulted in 16.3% of the overall
neuroactive drug costs. |
| doi_str_mv | 10.1176/ajp.144.6.778 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77561333</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77561333</sourcerecordid><originalsourceid>FETCH-LOGICAL-a295t-389251d5bee17473ef0df004a6b3175b21461380b73bdc49e5f120603ea420cc3</originalsourceid><addsrcrecordid>eNptkMtLxDAQh4Mouq4ePQoFxYPQNY_m0Zuy-AJBDwreQpqmbpa2iUl72P3rjewiIs5lGObjm-EHwAmCM4Q4u1JLP0NFMWMzzsUOmCBKaM4xFrtgAiHEeUnJ-wE4jHGZRkg43gf7hJY4DRNw_bJQoVPa5cbb2nTWte5jldk-Q4RlCxe9HVRr16bOol7YtfOLYHqrM68Ga_ohHoG9RrXRHG_7FLzd3b7OH_Kn5_vH-c1TrnBJh5yIElNU08oYxAtOTAPrBsJCsYogTiuMCoaIgBUnVa2L0tAGYcggMarAUGsyBRcbrw_uczRxkJ2N2rSt6o0bo-ScJkGqKTj7Ay7dGPr0m0QEQYYKwVmi8g2lg4sxmEb6YDsVVhJB-Z2rTLnKlKtkSS0Sf7q1jlVn6h96G2Tan2_3KmrVNkH12sYfTOBSCPatudxgynv767F_b34BkyeMJA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1310614876</pqid></control><display><type>article</type><title>Pharmaco-epidemiology in 136 hospitalized schizophrenic patients</title><source>MEDLINE</source><source>Psychiatry Legacy Collection Online Journals 1844-1996</source><source>Periodicals Index Online</source><creator>ZITO, J. M ; CRAIG, T. J ; WANDERLING, J ; SIEGEL, C</creator><creatorcontrib>ZITO, J. M ; CRAIG, T. J ; WANDERLING, J ; SIEGEL, C</creatorcontrib><description>The authors surveyed pharmacotherapy in a group of 136 newly admitted
patients with a DSM-III diagnosis of schizophrenia. They found that nine
antipsychotic agents were used; the median daily dose (in chlorpromazine
equivalents) was 1088 mg (mean +/- SD = 1428 +/- 1260 mg; range = 75-6186
mg). Women received greater mean daily doses of antipsychotics than men
(1688 versus 1284 mg). Using a Cox model survival analysis, the authors
found no statistical association between length of stay and the mean daily
dose of antipsychotic medication. The mean daily dose of high-potency
agents was 2.7 times greater than the dose of low-potency agents. The
excess exposure to haloperidol alone resulted in 16.3% of the overall
neuroactive drug costs.</description><identifier>ISSN: 0002-953X</identifier><identifier>EISSN: 1535-7228</identifier><identifier>DOI: 10.1176/ajp.144.6.778</identifier><identifier>PMID: 3592000</identifier><identifier>CODEN: AJPSAO</identifier><language>eng</language><publisher>Washington, DC: American Psychiatric Publishing</publisher><subject>Adolescent ; Adult ; Biological and medical sciences ; Dose-Response Relationship, Drug ; Drug Utilization - economics ; Female ; Haloperidol - administration & dosage ; Haloperidol - therapeutic use ; Hospitalization ; Humans ; Length of Stay ; Male ; Medical sciences ; Miscellaneous ; Neuropharmacology ; Pharmacology. Drug treatments ; Psychotropic Drugs - administration & dosage ; Psychotropic Drugs - therapeutic use ; Schizophrenia - drug therapy ; Sex Factors</subject><ispartof>The American journal of psychiatry, 1987-06, Vol.144 (6), p.778-782</ispartof><rights>1987 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a295t-389251d5bee17473ef0df004a6b3175b21461380b73bdc49e5f120603ea420cc3</citedby><cites>FETCH-LOGICAL-a295t-389251d5bee17473ef0df004a6b3175b21461380b73bdc49e5f120603ea420cc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://psychiatryonline.org/doi/epdf/10.1176/ajp.144.6.778$$EPDF$$P50$$Gappi$$H</linktopdf><linktohtml>$$Uhttps://psychiatryonline.org/doi/full/10.1176/ajp.144.6.778$$EHTML$$P50$$Gappi$$H</linktohtml><link.rule.ids>314,780,784,2859,21629,27869,27924,27925,77791,77792</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=8298868$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3592000$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ZITO, J. M</creatorcontrib><creatorcontrib>CRAIG, T. J</creatorcontrib><creatorcontrib>WANDERLING, J</creatorcontrib><creatorcontrib>SIEGEL, C</creatorcontrib><title>Pharmaco-epidemiology in 136 hospitalized schizophrenic patients</title><title>The American journal of psychiatry</title><addtitle>Am J Psychiatry</addtitle><description>The authors surveyed pharmacotherapy in a group of 136 newly admitted
patients with a DSM-III diagnosis of schizophrenia. They found that nine
antipsychotic agents were used; the median daily dose (in chlorpromazine
equivalents) was 1088 mg (mean +/- SD = 1428 +/- 1260 mg; range = 75-6186
mg). Women received greater mean daily doses of antipsychotics than men
(1688 versus 1284 mg). Using a Cox model survival analysis, the authors
found no statistical association between length of stay and the mean daily
dose of antipsychotic medication. The mean daily dose of high-potency
agents was 2.7 times greater than the dose of low-potency agents. The
excess exposure to haloperidol alone resulted in 16.3% of the overall
neuroactive drug costs.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Utilization - economics</subject><subject>Female</subject><subject>Haloperidol - administration & dosage</subject><subject>Haloperidol - therapeutic use</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Length of Stay</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychotropic Drugs - administration & dosage</subject><subject>Psychotropic Drugs - therapeutic use</subject><subject>Schizophrenia - drug therapy</subject><subject>Sex Factors</subject><issn>0002-953X</issn><issn>1535-7228</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>K30</sourceid><recordid>eNptkMtLxDAQh4Mouq4ePQoFxYPQNY_m0Zuy-AJBDwreQpqmbpa2iUl72P3rjewiIs5lGObjm-EHwAmCM4Q4u1JLP0NFMWMzzsUOmCBKaM4xFrtgAiHEeUnJ-wE4jHGZRkg43gf7hJY4DRNw_bJQoVPa5cbb2nTWte5jldk-Q4RlCxe9HVRr16bOol7YtfOLYHqrM68Ga_ohHoG9RrXRHG_7FLzd3b7OH_Kn5_vH-c1TrnBJh5yIElNU08oYxAtOTAPrBsJCsYogTiuMCoaIgBUnVa2L0tAGYcggMarAUGsyBRcbrw_uczRxkJ2N2rSt6o0bo-ScJkGqKTj7Ay7dGPr0m0QEQYYKwVmi8g2lg4sxmEb6YDsVVhJB-Z2rTLnKlKtkSS0Sf7q1jlVn6h96G2Tan2_3KmrVNkH12sYfTOBSCPatudxgynv767F_b34BkyeMJA</recordid><startdate>198706</startdate><enddate>198706</enddate><creator>ZITO, J. M</creator><creator>CRAIG, T. J</creator><creator>WANDERLING, J</creator><creator>SIEGEL, C</creator><general>American Psychiatric Publishing</general><general>American Psychiatric Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>HAWNG</scope><scope>HBMBR</scope><scope>IBDFT</scope><scope>K30</scope><scope>PAAUG</scope><scope>PAWHS</scope><scope>PAWZZ</scope><scope>PAXOH</scope><scope>PBHAV</scope><scope>PBQSW</scope><scope>PBYQZ</scope><scope>PCIWU</scope><scope>PCMID</scope><scope>PCZJX</scope><scope>PDGRG</scope><scope>PDWWI</scope><scope>PETMR</scope><scope>PFVGT</scope><scope>PGXDX</scope><scope>PIHIL</scope><scope>PISVA</scope><scope>PJCTQ</scope><scope>PJTMS</scope><scope>PLCHJ</scope><scope>PMHAD</scope><scope>PNQDJ</scope><scope>POUND</scope><scope>PPLAD</scope><scope>PQAPC</scope><scope>PQCAN</scope><scope>PQCMW</scope><scope>PQEME</scope><scope>PQHKH</scope><scope>PQMID</scope><scope>PQNCT</scope><scope>PQNET</scope><scope>PQSCT</scope><scope>PQSET</scope><scope>PSVJG</scope><scope>PVMQY</scope><scope>PZGFC</scope><scope>7X8</scope></search><sort><creationdate>198706</creationdate><title>Pharmaco-epidemiology in 136 hospitalized schizophrenic patients</title><author>ZITO, J. M ; CRAIG, T. J ; WANDERLING, J ; SIEGEL, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a295t-389251d5bee17473ef0df004a6b3175b21461380b73bdc49e5f120603ea420cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Utilization - economics</topic><topic>Female</topic><topic>Haloperidol - administration & dosage</topic><topic>Haloperidol - therapeutic use</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Length of Stay</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychotropic Drugs - administration & dosage</topic><topic>Psychotropic Drugs - therapeutic use</topic><topic>Schizophrenia - drug therapy</topic><topic>Sex Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ZITO, J. M</creatorcontrib><creatorcontrib>CRAIG, T. J</creatorcontrib><creatorcontrib>WANDERLING, J</creatorcontrib><creatorcontrib>SIEGEL, C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Periodicals Index Online Segment 13</collection><collection>Periodicals Index Online Segment 14</collection><collection>Periodicals Index Online Segment 27</collection><collection>Periodicals Index Online</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - West</collection><collection>Primary Sources Access (Plan D) - International</collection><collection>Primary Sources Access & Build (Plan A) - MEA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Midwest</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Northeast</collection><collection>Primary Sources Access (Plan D) - Southeast</collection><collection>Primary Sources Access (Plan D) - North Central</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Southeast</collection><collection>Primary Sources Access (Plan D) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - UK / I</collection><collection>Primary Sources Access (Plan D) - Canada</collection><collection>Primary Sources Access (Plan D) - EMEALA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - North Central</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - International</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - International</collection><collection>Primary Sources Access (Plan D) - West</collection><collection>Periodicals Index Online Segments 1-50</collection><collection>Primary Sources Access (Plan D) - APAC</collection><collection>Primary Sources Access (Plan D) - Midwest</collection><collection>Primary Sources Access (Plan D) - MEA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Canada</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - UK / I</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - EMEALA</collection><collection>Primary Sources Access & Build (Plan A) - APAC</collection><collection>Primary Sources Access & Build (Plan A) - Canada</collection><collection>Primary Sources Access & Build (Plan A) - West</collection><collection>Primary Sources Access & Build (Plan A) - EMEALA</collection><collection>Primary Sources Access (Plan D) - Northeast</collection><collection>Primary Sources Access & Build (Plan A) - Midwest</collection><collection>Primary Sources Access & Build (Plan A) - North Central</collection><collection>Primary Sources Access & Build (Plan A) - Northeast</collection><collection>Primary Sources Access & Build (Plan A) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - Southeast</collection><collection>Primary Sources Access (Plan D) - UK / I</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - APAC</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - MEA</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ZITO, J. M</au><au>CRAIG, T. J</au><au>WANDERLING, J</au><au>SIEGEL, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmaco-epidemiology in 136 hospitalized schizophrenic patients</atitle><jtitle>The American journal of psychiatry</jtitle><addtitle>Am J Psychiatry</addtitle><date>1987-06</date><risdate>1987</risdate><volume>144</volume><issue>6</issue><spage>778</spage><epage>782</epage><pages>778-782</pages><issn>0002-953X</issn><eissn>1535-7228</eissn><coden>AJPSAO</coden><abstract>The authors surveyed pharmacotherapy in a group of 136 newly admitted
patients with a DSM-III diagnosis of schizophrenia. They found that nine
antipsychotic agents were used; the median daily dose (in chlorpromazine
equivalents) was 1088 mg (mean +/- SD = 1428 +/- 1260 mg; range = 75-6186
mg). Women received greater mean daily doses of antipsychotics than men
(1688 versus 1284 mg). Using a Cox model survival analysis, the authors
found no statistical association between length of stay and the mean daily
dose of antipsychotic medication. The mean daily dose of high-potency
agents was 2.7 times greater than the dose of low-potency agents. The
excess exposure to haloperidol alone resulted in 16.3% of the overall
neuroactive drug costs.</abstract><cop>Washington, DC</cop><pub>American Psychiatric Publishing</pub><pmid>3592000</pmid><doi>10.1176/ajp.144.6.778</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-953X |
| ispartof | The American journal of psychiatry, 1987-06, Vol.144 (6), p.778-782 |
| issn | 0002-953X 1535-7228 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77561333 |
| source | MEDLINE; Psychiatry Legacy Collection Online Journals 1844-1996; Periodicals Index Online |
| subjects | Adolescent Adult Biological and medical sciences Dose-Response Relationship, Drug Drug Utilization - economics Female Haloperidol - administration & dosage Haloperidol - therapeutic use Hospitalization Humans Length of Stay Male Medical sciences Miscellaneous Neuropharmacology Pharmacology. Drug treatments Psychotropic Drugs - administration & dosage Psychotropic Drugs - therapeutic use Schizophrenia - drug therapy Sex Factors |
| title | Pharmaco-epidemiology in 136 hospitalized schizophrenic patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T19%3A51%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmaco-epidemiology%20in%20136%20hospitalized%20schizophrenic%20patients&rft.jtitle=The%20American%20journal%20of%20psychiatry&rft.au=ZITO,%20J.%20M&rft.date=1987-06&rft.volume=144&rft.issue=6&rft.spage=778&rft.epage=782&rft.pages=778-782&rft.issn=0002-953X&rft.eissn=1535-7228&rft.coden=AJPSAO&rft_id=info:doi/10.1176/ajp.144.6.778&rft_dat=%3Cproquest_cross%3E77561333%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1310614876&rft_id=info:pmid/3592000&rfr_iscdi=true |